LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/People In The News/Plaisier Takes Over Regulatory Affairs at FDA
People In The News

Plaisier Takes Over Regulatory Affairs at FDA

September 5, 2013 2 min read Premium comments

Advertisement

Plaisier Takes Over Regulatory Affairs at FDA
Melinda Plaisier

The FDA has a new sheriff in charge of regulatory compliance and enforcement.

On September 3, 2013, FDA Commissioner Margaret Hamburg, M.D. announced in an email to FDA staffers that Melinda Plaisier would become the agency’s new permanent Associate Commissioner for Regulatory Affairs (ACRA). She had been the acting commissioner since last October.

Inspections, Investigations, Compliance and Enforcement

The position has responsibility for over 4, 000 staff and operations in the Office of Regulatory Affairs (ORA), Global Regulatory Operations and Policy. ORA has responsibility for imports, inspections and investigations, compliance and enforcement, and field laboratory operations.

ORA supports FDA’s product centers by inspecting regulated products and manufacturers, analyzing samples of regulated products, reviewing imported products offered for entry into the U.S., and responding to public health emergencies. ORA also works with other Federal, State, Local, Tribal and Territorial, as well as foreign regulatory counterparts to further FDA’s mission.

Plaisier has been with the agency since 1995 and was made acting ACRA after Dara Corrigan announced she was assuming the position of director of FDA’s Europe Office and as senior advisor for global operations.

“As many of you know, Melinda has been steadfastly serving in this position in an acting role since October 1, 2012, ” Hamburg reportedly wrote. “During that time, Melinda has led the Office of Regulatory Affairs (ORA), utilizing her deep operational knowledge, her proven leadership skills, and her professional and collaborative demeanor.”

Hamburg added, “Going forward, Melinda will play a critical role in helping FDA adapt to the continuing program-based specialization within FDA’s regulated industries and in implementing FDA’s expanded authority in recent groundbreaking legislation in many important areas. I am confident that Melinda will help position FDA as a public health regulatory agency fully prepared to deal with the many challenges of an increasingly complex global regulatory environment.”

Advertisement

Plaisier will report to the deputy commissioner for global regulatory operations and policy (GO), a position that remained unfilled after it was vacated by Autor.

According to her FDA bio, Plaisier began her career in public policy, working in the U.S. Congress for over a decade. After joining the agency in 1995, she spent more than 13 years in the Office of the Commissioner, where she served as the Associate Commissioner for Legislation, providing executive leadership in directing and managing the agency’s congressional relations and legislative activities.  She also served as the Associate Commissioner for International Programs, where she focused on negotiating international agreements and working with developing nations.

Before becoming the Acting ACRA, Plaisier served as the Regional Food and Drug Director (RFDD) for the Central Region. As the RFDD, she provided executive leadership in directing and managing the programs of FDA within the 15 states of the Central Region. She has been recognized for her leadership and management contributions with numerous agency honor awards, including FDA’s highest award, the Award of Merit. In 2004 and again in 2009, she was awarded the Presidential Meritorious Rank Award for exceptional long-term accomplishments in the Senior Executive Service.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy